Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals
| Autor: | Roeland E Wasmann, Cornelis Smit, Roger J. M. Brüggemann, René M J Wiezer, Jill Adler-Moore, David M. Burger, Eric P H van Dongen, Yvo de Beer, Catherijne A. J. Knibbe |
|---|---|
| Přispěvatelé: | RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, MUMC+: DA KFT Laboratorium (9) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Antifungal Agents optimal dosing Morbidly obese Gastroenterology Fixed dose DEOXYCHOLATE Pharmacokinetics population pharmacokinetics Internal medicine Amphotericin B Medicine Humans AMBISOME In patient Dosing Prospective Studies Prospective cohort study obese business.industry fungal infection fungal treatment PHARMACODYNAMICS Obesity Morbid Clinical trial lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] Infectious Diseases SAFETY Liposomal amphotericin WEIGHT business |
| Zdroj: | Clinical Infectious Diseases, 70, 2213-2215 Clinical Infectious Diseases, 70(10):ciz885, 2213-2215. Oxford University Press Clinical Infectious Diseases, 70(10), 2213-2215. Oxford University Press Clinical Infectious Diseases, 70, 10, pp. 2213-2215 |
| ISSN: | 1058-4838 |
| DOI: | 10.1093/cid/ciz885 |
| Popis: | Contains fulltext : 220654.pdf (Publisher’s version ) (Open Access) In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|